Professor Lee obtained his undergraduate degree in pharmacy from the University of Washington in Seattle, USA, and his subsequent higher qualifications from the Chinese University of Hong Kong (CUHK) and the University of Oxford, UK.

He is widely recognized as one of the pioneers in pharmacoeconomics and outcomes research in Asia, and was the founding president of the Hong Kong Chapter of the International Society for Pharmacoeconomics and Outcomes Research that was established in 1999. Prof Lee was Professor and Associate Director of External Affairs of the Chinese University of Hong Kong’s School of Pharmacy of which he was a founding member before he moved to Malaysia.

His concurrent academic appointments include Adjunct Professor of the CUHK School of Pharmacy, Honorary Professor of the Li Ka Shing Faculty of Medicine of the University of Hong Kong, and Visiting Professor of the University of London School of Pharmacy, UK (2008-2011). Professor Lee has also maintained very close links with academic institutions in Mainland China for many years and has served as visiting scholar at a number of universities there.

He was appointed by the Government of Hong Kong as a Justice of the Peace in 2003 for his outstanding community services. He has published extensively in international peer-reviewed journals. He has been Editor-in-Chief of Journal of Medical Economics (UK) since 2006 and recently appointed as Co-Editor of Value in Health Regional Issue (US).

Health economics/pharmacoeconomics - measurement and valuation of health, including preference-based generic instruments and discrete choice experiments as well as the analysis of patient level data and decision-analytic modelling. Professor Kenneth also focusses on a critical examination of the validity of such evaluations in the global context generally and in emerging economies in particular. While continuing to contribute to and promote model investigations into the cost-efficiency and outcomes of new interventions, his research is now increasingly moving towards robust large studies that will offer planners and policy makers a far less speculative lever for making important broad decisions on health care.